Cargando…

Cost Effectiveness of Cryptococcal Antigen Screening as a Strategy to Prevent HIV-Associated Cryptococcal Meningitis in South Africa

OBJECTIVES: Cryptococcal meningitis (CM)-related mortality may be prevented by screening patients for sub-clinical cryptococcal antigenaemia (CRAG) at antiretroviral-therapy (ART) initiation and pre-emptively treating those testing positive. Prior to programmatic implementation in South Africa we pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Jarvis, Joseph N., Harrison, Thomas S., Lawn, Stephen D., Meintjes, Graeme, Wood, Robin, Cleary, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716603/
https://www.ncbi.nlm.nih.gov/pubmed/23894442
http://dx.doi.org/10.1371/journal.pone.0069288
_version_ 1782277559564632064
author Jarvis, Joseph N.
Harrison, Thomas S.
Lawn, Stephen D.
Meintjes, Graeme
Wood, Robin
Cleary, Susan
author_facet Jarvis, Joseph N.
Harrison, Thomas S.
Lawn, Stephen D.
Meintjes, Graeme
Wood, Robin
Cleary, Susan
author_sort Jarvis, Joseph N.
collection PubMed
description OBJECTIVES: Cryptococcal meningitis (CM)-related mortality may be prevented by screening patients for sub-clinical cryptococcal antigenaemia (CRAG) at antiretroviral-therapy (ART) initiation and pre-emptively treating those testing positive. Prior to programmatic implementation in South Africa we performed a cost-effectiveness analysis of alternative preventive strategies for CM. DESIGN: Cost-effectiveness analysis. METHODS: Using South African data we modelled the cost-effectiveness of four strategies for patients with CD4 cell-counts <100 cells/µl starting ART 1) no screening or prophylaxis (standard of care), 2) universal primary fluconazole prophylaxis, 3) CRAG screening with fluconazole treatment if antigen-positive, 4) CRAG screening with lumbar puncture if antigen-positive and either amphotericin-B for those with CNS disease or fluconazole for those without. Analysis was limited to the first year of ART. RESULTS: The least costly strategy was CRAG screening followed by high-dose fluconazole treatment of all CRAG-positive individuals. This strategy dominated the standard of care at CRAG prevalence ≥0.6%. Although CRAG screening followed by lumbar puncture in all antigen-positive individuals was the most effective strategy clinically, the incremental benefit of LPs and amphotericin therapy for those with CNS disease was small and additional costs were large (US$158 versus US$51per person year; incremental cost effectiveness ratio(ICER) US$889,267 per life year gained). Both CRAG screening strategies are less costly and more clinically effective than current practice. Primary prophylaxis is more effective than current practice, but relatively cost-ineffective (ICER US$20,495). CONCLUSIONS: CRAG screening would be a cost-effective strategy to prevent CM-related mortality among patients initiating ART in South Africa. These findings provide further justification for programmatic implementation of CRAG screening.
format Online
Article
Text
id pubmed-3716603
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-37166032013-07-26 Cost Effectiveness of Cryptococcal Antigen Screening as a Strategy to Prevent HIV-Associated Cryptococcal Meningitis in South Africa Jarvis, Joseph N. Harrison, Thomas S. Lawn, Stephen D. Meintjes, Graeme Wood, Robin Cleary, Susan PLoS One Research Article OBJECTIVES: Cryptococcal meningitis (CM)-related mortality may be prevented by screening patients for sub-clinical cryptococcal antigenaemia (CRAG) at antiretroviral-therapy (ART) initiation and pre-emptively treating those testing positive. Prior to programmatic implementation in South Africa we performed a cost-effectiveness analysis of alternative preventive strategies for CM. DESIGN: Cost-effectiveness analysis. METHODS: Using South African data we modelled the cost-effectiveness of four strategies for patients with CD4 cell-counts <100 cells/µl starting ART 1) no screening or prophylaxis (standard of care), 2) universal primary fluconazole prophylaxis, 3) CRAG screening with fluconazole treatment if antigen-positive, 4) CRAG screening with lumbar puncture if antigen-positive and either amphotericin-B for those with CNS disease or fluconazole for those without. Analysis was limited to the first year of ART. RESULTS: The least costly strategy was CRAG screening followed by high-dose fluconazole treatment of all CRAG-positive individuals. This strategy dominated the standard of care at CRAG prevalence ≥0.6%. Although CRAG screening followed by lumbar puncture in all antigen-positive individuals was the most effective strategy clinically, the incremental benefit of LPs and amphotericin therapy for those with CNS disease was small and additional costs were large (US$158 versus US$51per person year; incremental cost effectiveness ratio(ICER) US$889,267 per life year gained). Both CRAG screening strategies are less costly and more clinically effective than current practice. Primary prophylaxis is more effective than current practice, but relatively cost-ineffective (ICER US$20,495). CONCLUSIONS: CRAG screening would be a cost-effective strategy to prevent CM-related mortality among patients initiating ART in South Africa. These findings provide further justification for programmatic implementation of CRAG screening. Public Library of Science 2013-07-19 /pmc/articles/PMC3716603/ /pubmed/23894442 http://dx.doi.org/10.1371/journal.pone.0069288 Text en © 2013 Jarvis et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Jarvis, Joseph N.
Harrison, Thomas S.
Lawn, Stephen D.
Meintjes, Graeme
Wood, Robin
Cleary, Susan
Cost Effectiveness of Cryptococcal Antigen Screening as a Strategy to Prevent HIV-Associated Cryptococcal Meningitis in South Africa
title Cost Effectiveness of Cryptococcal Antigen Screening as a Strategy to Prevent HIV-Associated Cryptococcal Meningitis in South Africa
title_full Cost Effectiveness of Cryptococcal Antigen Screening as a Strategy to Prevent HIV-Associated Cryptococcal Meningitis in South Africa
title_fullStr Cost Effectiveness of Cryptococcal Antigen Screening as a Strategy to Prevent HIV-Associated Cryptococcal Meningitis in South Africa
title_full_unstemmed Cost Effectiveness of Cryptococcal Antigen Screening as a Strategy to Prevent HIV-Associated Cryptococcal Meningitis in South Africa
title_short Cost Effectiveness of Cryptococcal Antigen Screening as a Strategy to Prevent HIV-Associated Cryptococcal Meningitis in South Africa
title_sort cost effectiveness of cryptococcal antigen screening as a strategy to prevent hiv-associated cryptococcal meningitis in south africa
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716603/
https://www.ncbi.nlm.nih.gov/pubmed/23894442
http://dx.doi.org/10.1371/journal.pone.0069288
work_keys_str_mv AT jarvisjosephn costeffectivenessofcryptococcalantigenscreeningasastrategytopreventhivassociatedcryptococcalmeningitisinsouthafrica
AT harrisonthomass costeffectivenessofcryptococcalantigenscreeningasastrategytopreventhivassociatedcryptococcalmeningitisinsouthafrica
AT lawnstephend costeffectivenessofcryptococcalantigenscreeningasastrategytopreventhivassociatedcryptococcalmeningitisinsouthafrica
AT meintjesgraeme costeffectivenessofcryptococcalantigenscreeningasastrategytopreventhivassociatedcryptococcalmeningitisinsouthafrica
AT woodrobin costeffectivenessofcryptococcalantigenscreeningasastrategytopreventhivassociatedcryptococcalmeningitisinsouthafrica
AT clearysusan costeffectivenessofcryptococcalantigenscreeningasastrategytopreventhivassociatedcryptococcalmeningitisinsouthafrica